Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Finch Therapeutics Group, Inc. (FNCH : NSDQ)
 
 • Company Description   
Finch Therapeutics Group Inc. is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery(R) platform to develop a novel class of orally administered biological drugs. The company's product candidate includes CP101, FIN-211, FIN-524 and FIN-525. Finch Therapeutics Group Inc. is based in SOMERVILLE, Mass.

Number of Employees:

 
 • Price / Volume Information   
Yesterday's Closing Price: $15.32 Daily Weekly Monthly
20 Day Moving Average: 117,473 shares
Shares Outstanding: 47.48 (millions)
Market Capitalization: $727.38 (millions)
Beta:
52 Week High: $22.50
52 Week Low: $11.56
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 9.51% 12.92%
12 Week 3.16% 2.14%
Year To Date % %
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
200 Inner Belt Road Suite 400
-
Somerville,MA 02143
USA
ph: 617-229-6499
fax: -
ir@finchtherapeutics.com http://www.finchtherapeutics.com
 
 • General Corporate Information   
Officers
- - -
- - -
- - -
- - -
- - -

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 31773D101
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/21
Next Expected EPS Date: 02/09/22
Share - Related Items
Shares Outstanding: 47.48
Most Recent Split Date: (:1)
Beta:
Market Capitalization: $727.38 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.32 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.72 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 22.28% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 02/09/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 3.31
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 34.38%
Sales Growth
vs. Year Ago Period: 540.49%
vs. Previous Quarter: 300.81%
ROE
09/30/21 - -
06/30/21 - -
03/31/21 - -
ROA
09/30/21 - -
06/30/21 - -
03/31/21 - -
Current Ratio
09/30/21 - 17.64
06/30/21 - 18.58
03/31/21 - 17.24
Quick Ratio
09/30/21 - 17.64
06/30/21 - 18.58
03/31/21 - 17.24
Operating Margin
09/30/21 - -
06/30/21 - -
03/31/21 - -
Net Margin
09/30/21 - -
06/30/21 - -
03/31/21 - -
Pre-Tax Margin
09/30/21 - -
06/30/21 - -
03/31/21 - -
Book Value
09/30/21 - 4.63
06/30/21 - 4.81
03/31/21 - 5.08
Inventory Turnover
09/30/21 - -
06/30/21 - -
03/31/21 - -
Debt-to-Equity
09/30/21 - 0.00
06/30/21 - 0.00
03/31/21 - 0.01
Debt-to-Capital
09/30/21 - 0.00
06/30/21 - 0.00
03/31/21 - 0.75
 

Powered by Zacks Investment Research ©